• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在接受短期达雷妥尤单抗治疗复发多发性骨髓瘤后发生的爱泼斯坦-巴尔病毒驱动的霍奇金淋巴瘤

Epstein-Barr Virus Driven Hodgkin's Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma.

作者信息

Mohammadi-Oroujeh Moeen, Mehreen Ansa, Grinblatt David L

机构信息

Department of Internal Medicine, University of Chicago (NorthShore), Chicago, IL, USA.

Department of Pathology, University of Chicago (NorthShore), Chicago, IL, USA.

出版信息

Case Rep Hematol. 2023 Dec 18;2023:6669174. doi: 10.1155/2023/6669174. eCollection 2023.

DOI:10.1155/2023/6669174
PMID:38146540
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10749716/
Abstract

In this case, we describe the potential risk of developing an infectious complication leading to a secondary malignancy after a short course of immunotherapy. We report a patient who presented with Epstein-Barr virus (EBV) driven Hodgkin's lymphoma after treatment with a short course of daratumumab along with pomalidomide and dexamethasone for relapsed multiple myeloma. Although there have been limited documented cases of daratumumab treatment leading to EBV reactivation, in patients presenting with infectious symptoms or neutropenia on a daratumumab-based regimen, testing for EBV should not be overlooked.

摘要

在这种情况下，我们描述了在短疗程免疫治疗后发生感染性并发症并导致继发性恶性肿瘤的潜在风险。我们报告了一名患者，该患者在接受短疗程达雷妥尤单抗联合泊马度胺和地塞米松治疗复发的多发性骨髓瘤后，出现了由 Epstein-Barr 病毒（EBV）驱动的霍奇金淋巴瘤。尽管有记录的达雷妥尤单抗治疗导致 EBV 重新激活的病例有限，但对于接受基于达雷妥尤单抗方案治疗且出现感染症状或中性粒细胞减少的患者，不应忽视 EBV 检测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c801/10749716/9aee691e8feb/CRIHEM2023-6669174.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c801/10749716/d7d7e8e4852b/CRIHEM2023-6669174.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c801/10749716/9aee691e8feb/CRIHEM2023-6669174.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c801/10749716/d7d7e8e4852b/CRIHEM2023-6669174.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c801/10749716/9aee691e8feb/CRIHEM2023-6669174.002.jpg

相似文献

1
Epstein-Barr Virus Driven Hodgkin's Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma.在接受短期达雷妥尤单抗治疗复发多发性骨髓瘤后发生的爱泼斯坦-巴尔病毒驱动的霍奇金淋巴瘤
Case Rep Hematol. 2023 Dec 18;2023:6669174. doi: 10.1155/2023/6669174. eCollection 2023.
2
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.皮下注射达雷妥尤单抗联合泊马度胺和地塞米松与泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤患者（APOLLO）：一项开放标签、随机、多中心、3 期临床试验的随访扩展。
Lancet Haematol. 2023 Oct;10(10):e813-e824. doi: 10.1016/S2352-3026(23)00218-1.
3
AIDS-related lymphoma in Brazil. Histopathology, immunophenotype, and association with Epstein-Barr virus.巴西的艾滋病相关淋巴瘤。组织病理学、免疫表型及与爱泼斯坦-巴尔病毒的关联
Am J Clin Pathol. 1996 Feb;105(2):230-7. doi: 10.1093/ajcp/105.2.230.
4
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.达雷妥尤单抗联合泊马度胺和地塞米松与泊马度胺和地塞米松单药治疗既往治疗的多发性骨髓瘤（APOLLO）：一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5.
5
Hemophagocytic Lymphohistiocytosis as the Presenting Manifestation of Relapsed Classic Hodgkin's Lymphoma in the Presence of Concurrent Human Immunodeficiency Virus, Genital Herpes, Epstein-Barr Virus and Mycobacterium Avium Complex Infection.噬血细胞性淋巴组织细胞增生症作为复发性经典型霍奇金淋巴瘤在合并人类免疫缺陷病毒、生殖器疱疹、爱泼斯坦-巴尔病毒及鸟分枝杆菌复合群感染时的首发表现
Cureus. 2020 Nov 19;12(11):e11563. doi: 10.7759/cureus.11563.
6
Molecular detection of Epstein-Barr virus in different types of lymphoma.检测不同类型淋巴瘤中的 Epstein-Barr 病毒。
Mol Biol Rep. 2020 Mar;47(3):1803-1807. doi: 10.1007/s11033-020-05274-0. Epub 2020 Jan 29.
7
Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma.在爱泼斯坦-巴尔病毒阳性的霍奇金淋巴瘤中与HLA I类相关，在爱泼斯坦-巴尔病毒阴性的霍奇金淋巴瘤中与HLA III类相关。
Lancet. 2005;365(9478):2216-24. doi: 10.1016/S0140-6736(05)66780-3.
8
Epstein-Barr virus viral load and serology in childhood non-Hodgkin's lymphoma and chronic inflammatory conditions in Uganda: implications for disease risk and characteristics.在乌干达，儿童非霍奇金淋巴瘤和慢性炎症性疾病中，Epstein-Barr 病毒病毒载量和血清学：对疾病风险和特征的影响。
J Med Virol. 2014 Oct;86(10):1796-803. doi: 10.1002/jmv.23988. Epub 2014 Jun 2.
9
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.来那度胺治疗后复发或难治性多发性骨髓瘤日本患者的泊马度胺、地塞米松和达雷妥尤单抗。
Int J Hematol. 2022 Jul;116(1):122-130. doi: 10.1007/s12185-022-03338-4. Epub 2022 Apr 16.
10
The prevalence of Epstein-Barr virus infection in head and neck non-Hodgkin's lymphomas in Khorasan, northeast of Iran.伊朗东北部霍拉桑地区头颈部非霍奇金淋巴瘤中爱泼斯坦-巴尔病毒感染的患病率
J Pak Med Assoc. 2013 Jul;63(7):882-7.

本文引用的文献

1
EBV-related lymphoma after long-term daratumumab treatment: a case report.长期使用达雷妥尤单抗治疗后发生的EB病毒相关淋巴瘤：一例报告
Blood Cancer J. 2020 Nov 4;10(11):113. doi: 10.1038/s41408-020-00379-y.
2
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.来那度胺治疗后复发/难治性多发性骨髓瘤患者采用泊马度胺、地塞米松和达雷妥尤单抗治疗。
Leukemia. 2020 Dec;34(12):3286-3297. doi: 10.1038/s41375-020-0813-1. Epub 2020 May 6.
3
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.
达雷妥尤单抗联合来那度胺和地塞米松治疗复发或复发/难治性多发性骨髓瘤患者的持久疗效和耐受性（GEN503）：一项开放标签的1/2期研究的最终结果
Br J Haematol. 2019 Aug;186(3):e35-e39. doi: 10.1111/bjh.15879. Epub 2019 Mar 31.
4
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.达雷妥尤单抗、来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤的东亚患者：III 期 POLLUX 研究的亚组分析。
Blood Cancer J. 2018 May 1;8(4):41. doi: 10.1038/s41408-018-0071-x.
5
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
6
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.来那度胺、沙利度胺和泊马度胺通过磷酸肌醇3激酶信号传导和IKAROS表达重新激活爱泼斯坦-巴尔病毒裂解周期。
Clin Cancer Res. 2016 Oct 1;22(19):4901-4912. doi: 10.1158/1078-0432.CCR-15-2242. Epub 2016 Jun 13.
7
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.Daratumumab 单药治疗多发性骨髓瘤中针对 CD38。
N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26.
8
The Epstein-Barr virus and the pathogenesis of lymphoma.EB 病毒与淋巴瘤发病机制。
J Pathol. 2015 Jan;235(2):312-22. doi: 10.1002/path.4459.
9
Glucocorticoids activate Epstein Barr virus lytic replication through the upregulation of immediate early BZLF1 gene expression.糖皮质激素通过上调早期 BZLF1 基因的表达来激活 Epstein Barr 病毒的裂解复制。
Brain Behav Immun. 2010 Oct;24(7):1089-96. doi: 10.1016/j.bbi.2010.04.013. Epub 2010 May 11.